EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial

Aída García-González, Alejandro Matamoros-Domínguez, Juan Manuel Espinosa-Cabello, Gisela Pérez-Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque-Cuellar, Silvia García-Rey, Andrés Jiménez-Sánchez, Antonio Jesús Martínez-Ortega, Miguel Ángel Mangas-Cruz, Isabel Cerrillo, Javier S Perona iD und 3 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71206 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Aída García-González und 14 weiteren Autor:innen. Beteiligte Einrichtung: Spanish Scientific Research Council, Instituto de la Grasa-CSIC, Seville, Spain. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Kidney, Oleanolic Acid. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Spanish Ministry of Science and Innovation/Spanish State Research Agency (Agencia Estatal de Investigación, AEI), the Andalusian Regional Government/Regional Ministry of University, Research and Innovation and the European Social Fund Plus (ESF+), European Union through the Next Generation EU funds and the Recovery, Transformation and Resilience Plan, and by the Ministry of Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism. In this prespecified, exploratory secondary analysis of the OLTRAD trial, we evaluated whether long‐term intake of OA‐enriched olive oil attenuates kidney function decline in patients with T2DM.

Methods

In the OLTRAD randomised controlled trial, 97 patients with T2DM were assigned to consume OA‐enriched olive oil (600 mg OA/kg) or control olive oil for 12 months, alongside standard therapy. Kidney outcomes included estimated glomerular filtration rate (eGFR) and urinary albumin‐to‐creatinine ratio (uACR). Circulating AGEs (methylglyoxal [MG], carboxymethyllysine [CML]), enzymes involved in AGE metabolism (aldose reductase [AR], glyoxalase‐I [GloxI]), and oxidative stress markers (ROS and MDA) were assessed.

Results

OA‐enriched olive oil attenuated eGFR decline relative to control, an effect restricted to participants with mildly impaired eGFR at baseline (60–90 mL/min/1.73 m 2 ; time × group interaction p = 0.010), with no significant interaction among participants with normal baseline eGFR. OA‐enriched oil also prevented the rise in uACR observed with control oil. Mechanistically, OA reduced AR concentration and increased GloxI activity, resulting in lower circulating MG, whereas CML remained unchanged. OA‐enriched oil further reduced ROS and MDA levels, while MDA increased with control oil.

Conclusions

In this exploratory, hypothesis‐generating secondary analysis, long‐term consumption of OA‐enriched olive oil was associated with attenuated kidney function decline in patients with T2DM, an effect limited to those with baseline mildly impaired eGFR. These changes were associated with modulation of AGE‐related pathways and reduced oxidative stress. As the trial was powered for glycemic control rather than renal outcomes, larger, adequately powered studies are needed to confirm these findings before their clinical relevance can be established. Trial Registration: Clinicaltrials.gov identifier: NCT06030544; https://clinicaltrials.gov/study/NCT06030544

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesKidneyOleanolic AcidOlive OilRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedAlbuminuriaGlomerular Filtration RateGlycation End Products, AdvancedOxidative Stress

Stichwörter der Autor:innen

OA‐enriched olive oiladvanced glycation end productschronic kidney diseaseoleanolic acid (OA)randomised controlled trialtype 2 diabetes mellitus

Substanzen

Glycation End Products, AdvancedOleanolic AcidOlive Oil

Autor:innen und Institutionen

  • Spanish Scientific Research Council, Instituto de la Grasa-CSIC, Seville, Spain.
  • Regional Andalusian Health Service, Service of Endocrinology and Nutrition, University Hospitals Virgen del Rocío, Seville, Spain.
  • Area of Nutrition and Food Sciences, Department of Molecular Biology and Biochemistry Engineering, Universidad Pablo de Olavide, Seville, Spain.
  • CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Madrid, Spain.

ORCID-Profile: Javier S Perona, Elena María Yubero-Serrano, José María Castellano

Förderung

  • Spanish Ministry of Science and Innovation/Spanish State Research Agency (Agencia Estatal de Investigación, AEI)
  • the Andalusian Regional Government/Regional Ministry of University, Research and Innovation and the European Social Fund Plus (ESF+)
  • European Union through the Next Generation EU funds and the Recovery, Transformation and Resilience Plan, and by the Ministry of Universities

Zitieren

APA

García-González, A., Matamoros-Domínguez, A., Espinosa-Cabello, J. M., Pérez-Muñoz, G., Aranda, M. J. L., Roque-Cuellar, M. D. C., García-Rey, S., Jiménez-Sánchez, A., Martínez-Ortega, A. J., Mangas-Cruz, M. Á., Cerrillo, I., Perona, J. S., García-Luna, P. P., Yubero-Serrano, E. M., & Castellano, J. M. (2026). Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71206

Vancouver

García-González A, Matamoros-Domínguez A, Espinosa-Cabello JM, Pérez-Muñoz G, Aranda MJL, Roque-Cuellar MDC, et al. Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71206

BibTeX
@article{GarcaGonzlez2026,
  author = {García-González, Aída and Matamoros-Domínguez, Alejandro and Espinosa-Cabello, Juan Manuel and Pérez-Muñoz, Gisela and Aranda, Manuel Jesús León and Roque-Cuellar, María Del Carmen and García-Rey, Silvia and Jiménez-Sánchez, Andrés and Martínez-Ortega, Antonio Jesús and Mangas-Cruz, Miguel Ángel and Cerrillo, Isabel and Perona, Javier S and García-Luna, Pedro Pablo and Yubero-Serrano, Elena María and Castellano, José María},
  title = {Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71206}
}
Kostenlos starten →